Natera Gains EU IVDR Certification for Signatera, But Operating Leverage Remains the Core Test

What happened

Natera announced that its Signatera MRD test received Class C certification under the EU's IVDR, signaling a rigorous regulatory green light for European commercialization. While this expands Natera's addressable market and diversifies geographic risk, the certification does not alter the fundamental near-term challenge: Q1 2026 operating losses widened to $93.5 million despite 39% revenue growth, and the company continues to burn cash on R&D and SG&A. CEO insider selling on June 4 (40,000 shares) adds a note of caution. The IVDR win is a positive regulatory step, but the stock at ~$219 already prices in sustained MRD compounding; the real catalyst remains visible operating leverage, not regulatory milestones alone.

Implication

The certification strengthens Natera's international revenue base and validates its regulatory capability, potentially supporting a broader reimbursement strategy in Europe. However, European MRD pricing is likely lower than US commercial rates, and volume ramp will be gradual. The fundamental thesis hinges on whether Natera can convert scale into narrowing losses; this event adds optionality but does not change the calculus. Investors should watch for EU reimbursement decisions and whether the Foresight integration delivers on its 2026 clinical launch timeline.

Thesis delta

The IVDR certification adds a tangible regulatory milestone to the international expansion thesis, previously centered on Japan. It increases confidence in Natera's regulatory capabilities and expands the addressable market, but does not shift the core wait-and-see stance on operating leverage. The ratio of positive events to ongoing financial drag remains similar, and the key variable—whether the company can demonstrate improved operating leverage in Q2 2026—is unchanged.